Newron Pharmaceuticals SpA operates as a biopharmaceutical company. The company is headquartered in Bresso, Milano and currently employs 22 full-time employees. The company went IPO on 2006-12-12. The company focuses on the discovery and development of pharmaceutical products. The firm is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The firm undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.
Follow-Up Questions
Who is the CEO of Newron Pharmaceuticals SpA?
Prof. Stefan Weber is the Chief Executive Officer of Newron Pharmaceuticals SpA, joining the firm since 2005.
What is the price performance of NWPHF stock?
The current price of NWPHF is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Newron Pharmaceuticals SpA?
Newron Pharmaceuticals SpA belongs to Pharmaceuticals industry and the sector is Health Care
What is Newron Pharmaceuticals SpA market cap?
Newron Pharmaceuticals SpA's current market cap is $0
Is Newron Pharmaceuticals SpA a buy, sell, or hold?
According to wall street analysts, 5 analysts have made analyst ratings for Newron Pharmaceuticals SpA, including 3 strong buy, 4 buy, 1 hold, 0 sell, and 3 strong sell
